OncoMed to Present Data on Multiple Anti-Cancer Stem Cell Candidates at the American Association of Cancer Research Meeting

REDWOOD CITY, Calif., March 19, 2015 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (Nasdaq:OMED) will present new data related to its clinical and preclinical anti-cancer stem cell and immuno-oncology candidates in a total of seven presentations at the upcoming American Association of Cancer Research (AACR) Meeting to be held April 18-22, 2015 in Philadelphia, PA.

Among the presentations will be data looking at synergies between anti-DLL4 and anti-PD1 antibodies, as well as between Wnt-pathway inhibitors and taxanes; biomarker research for tarextumab (anti-Notch2/3), brontictuzumab (anti-Notch1) and anti-RSPO3; and research related to the Hippo anti-cancer stem cell pathway. The following abstracts have been selected for presentation by OncoMed scientists:

Sunday, April 19, 2015 1:00 PM - 5:00 PM
1. "Dual Targeting of Delta-like ligand 4 (DLL4) and Programmed Death 1 (PD1) inhibits tumor growth and generate enhanced long-term immunological memory"
Abstract Number: 255
Presenting author: Minu Srivastava, Ph.D.
Session: Immune Checkpoints
Monday, April 20, 2015 8:00 AM - 12:00 PM
"Development and validation of a biomarker for prospective selection of Notch1 activation in patients with certain advanced solid tumors in a first-in-human Phase1 study of the cancer stem cell targeting antibody OMP-52M51 (anti-Notch1)"
Abstract number: 1549
Presenting author: Ann Kapoun, Ph.D.
Session: Therapeutic Targeting of the Microenvironment
Monday, April 20, 2015 1:00 PM - 5:00 PM
3. "Enhanced antitumor efficacy by sequential application of Wnt pathway antagonists in combination with taxanes"
Abstract Number: 2576
Presenting author: Wan-Ching Yen, Ph.D., OncoMed Pharmaceuticals
Session Title: DNA Damaging and Antimitotic Agents and Cytotoxicity Modulators
4. "Tarextumab (Anti-NOTCH2/3) reverses NOTCH2 and NOTCH3-dependent tumorigenicity and metastases in small cell lung cancer"
Abstract number: 2323
Presenting author: Jalpa Shah
Session: Stem Cells and Development
5. "The Hippo signaling pathway mediates BMP inhibition of cancer stem cells"
Abstract number: 2322
Presenting author: Elsa Quintana, Ph.D.
Session: Stem Cells and Development
Tuesday, April 21, 2015 1:00 PM - 5:00 PM
6. "Wnt pathway antagonist ipafricept (FZD8-Fc, OMP-54F28) inhibits tumor growth and reduces tumor-initiating cell frequency in ovarian patient-derived xenograft models"
Abstract number: 4233
Presenting author: Marcus Fischer
Session: Therapeutics Targeting Cancer Stem Cells
"Discovery and evaluation of pharmacodynamic and predictive biomarkers for anti-RSPO3, a treatment that reduces tumor growth and cancer stem cell frequency in patient derived xenograft tumor models"
Abstract number: 4367
Presenting author: Fiore Cattaruzza, Ph.D.
Session: New Targets 1

About OncoMed Pharmaceuticals

OncoMed Pharmaceuticals is a clinical-stage company focused on discovering and developing novel therapeutics targeting cancer stem cells (CSCs). OncoMed has six anti-cancer product candidates in clinical development, the most advanced of which are in randomized Phase 2 clinical trials. Demcizumab (anti-DLL4, OMP-21M18), tarextumab (anti-Notch2/3, OMP-59R5), brontictuzumab (anti-Notch1, OMP-52M51), anti-DLL4/VEGF bispecific antibody (OMP-305B83), vantictumab (anti-FZD7, OMP-18R5), and ipafricept (FZD8-Fc, OMP-54F28) each target key cancer stem cell signaling pathways including Notch and Wnt. OncoMed plans to file an Investigational New Drug application in early 2015 for anti-RSPO3 (OMP-131R10), an antibody targeting a third key cancer stem cell signaling pathway called R-spondin-LGR. OncoMed is also pursuing discovery of additional novel anti-CSC and cancer immune-oncology product candidates. OncoMed has formed strategic alliances with Celgene Corporation, Bayer Pharma AG and GlaxoSmithKline (GSK). Additional information can be found at the company's website: www.oncomed.com.

CONTACT: Media & Investors OncoMed Pharmaceuticals Michelle Corral Senior Director, Investor Relations and Corporate Communications michelle.corral@oncomed.com (650) 995-8373 Investors Shari Annes Annes Associates shari.annes@oncomed.com (650) 888-0902

Source:OncoMed Pharmaceuticals, Inc.